These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1165 related items for PubMed ID: 33910273

  • 21. Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.
    Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, Vilella R, Frati C, Alfieri R, Ampollini L, Veneziani M, Silini EM, Ardizzoni A, Urbanek K, Aversa F, Quaini F, Tiseo M.
    Clin Cancer Res; 2018 Jan 15; 24(2):407-419. PubMed ID: 29074606
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Takashima Y, Sakakibara-Konishi J, Hatanaka Y, Hatanaka KC, Ohhara Y, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Matsuno Y, Nishimura M.
    Clin Lung Cancer; 2018 Jul 15; 19(4):352-359.e1. PubMed ID: 29544718
    [Abstract] [Full Text] [Related]

  • 24. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, Daigo Y.
    Lung Cancer; 2019 Nov 15; 137():56-63. PubMed ID: 31546072
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S, Faghih Z, Montazer M, Safaei A, Mokhtari M, Jafari P, Talei AR, Tahmasebi S, Ghaderi A.
    Cell Oncol (Dordr); 2019 Jun 15; 42(3):343-356. PubMed ID: 30825183
    [Abstract] [Full Text] [Related]

  • 27. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA.
    Arch Pathol Lab Med; 2018 Nov 15; 142(11):1388-1393. PubMed ID: 29431467
    [Abstract] [Full Text] [Related]

  • 28. Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis.
    Li J, Li L, Wang J, Liu N, Liu H, Xu F, Li M, Yuan S.
    Respir Res; 2024 Jun 17; 25(1):244. PubMed ID: 38886760
    [Abstract] [Full Text] [Related]

  • 29. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
    Kinoshita F, Takada K, Yamada Y, Oku Y, Kosai K, Ono Y, Tanaka K, Wakasu S, Oba T, Osoegawa A, Tagawa T, Shimokawa M, Oda Y, Mori M.
    Ann Surg Oncol; 2020 Jun 17; 27(6):2102-2109. PubMed ID: 31773516
    [Abstract] [Full Text] [Related]

  • 30. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y, Tsutani Y, Shiroma N, Kai Y, Mimae T, Miyata Y, Takeshima Y, Arihiro K, Okada M.
    Clin Lung Cancer; 2020 Jul 17; 21(4):e302-e314. PubMed ID: 32102750
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
    Wei Z, Zhan X, Fan L, Ye X, Yang X, Huang G, Li W, Wang J, Han X, Meng M, Ni Y, Li Q.
    Int J Hyperthermia; 2018 Jul 17; 35(1):591-598. PubMed ID: 30307348
    [Abstract] [Full Text] [Related]

  • 33. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 34. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.
    Clin Cancer Res; 2016 Dec 15; 22(24):6278-6289. PubMed ID: 27252415
    [Abstract] [Full Text] [Related]

  • 35. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X, Gao Y, Yang L, Jing H, Teng F, Huang Z, Xing L.
    Clin Lung Cancer; 2019 Jan 15; 20(1):48-58. PubMed ID: 30341017
    [Abstract] [Full Text] [Related]

  • 36. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.
    PLoS One; 2015 Jan 15; 10(8):e0136023. PubMed ID: 26313362
    [Abstract] [Full Text] [Related]

  • 37. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
    Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F.
    Mod Pathol; 2022 May 15; 35(5):601-608. PubMed ID: 34839351
    [Abstract] [Full Text] [Related]

  • 38. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer.
    Wang Q, Lou W, Di W, Wu X.
    Int Immunopharmacol; 2017 Nov 15; 52():7-14. PubMed ID: 28846888
    [Abstract] [Full Text] [Related]

  • 39. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R, Xu H, Lu Z, Huang J, Lei Y, Mao S, Wang Y, Feng X, Sun N, Wang Y, He J.
    Cancer Lett; 2020 Feb 01; 470():95-105. PubMed ID: 31644929
    [Abstract] [Full Text] [Related]

  • 40. Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
    Hashemi S, Fransen MF, Niemeijer A, Ben Taleb N, Houda I, Veltman J, Becker-Commissaris A, Daniels H, Crombag L, Radonic T, Jongeneel G, Tarasevych S, Looysen E, van Laren M, Tiemessen M, van Diepen V, Maassen-van den Brink K, Thunnissen E, Bahce I.
    Lung Cancer; 2021 Mar 01; 153():81-89. PubMed ID: 33465698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.